Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
Phillips AN, Bansi-Matharu L, Venter F, Havlir D, Pozniak A, Kuritzkes DR, Wensing A, Lundgren JD, Pillay D, Mellors J, Cambiano V, Jahn A, Apollo T, Mugurungi O, Ripin D, Da Silva J, Raizes E, Ford N, Siberry GK, Gupta RK, Barnabas R, Revill P, Cohn J, Calmy A, Bertagnolio S.
Phillips AN, et al. Among authors: bertagnolio s.
Lancet HIV. 2020 Mar;7(3):e193-e200. doi: 10.1016/S2352-3018(19)30400-X. Epub 2020 Feb 5.
Lancet HIV. 2020.
PMID: 32035041
Free PMC article.